Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) EBITDA (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EBITDA for 5 consecutive years, with -$9.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 53.72% to -$9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$60.7 million through Dec 2025, up 17.55% year-over-year, with the annual reading at -$60.7 million for FY2025, 17.55% up from the prior year.
  • EBITDA for Q4 2025 was -$9.4 million at Werewolf Therapeutics, up from -$15.7 million in the prior quarter.
  • The five-year high for EBITDA was -$6.1 million in Q2 2023, with the low at -$20.3 million in Q4 2024.
  • Average EBITDA over 5 years is -$14.0 million, with a median of -$14.4 million recorded in 2021.
  • The sharpest move saw EBITDA surged 59.48% in 2023, then tumbled 212.51% in 2024.
  • Over 5 years, EBITDA stood at -$17.9 million in 2021, then increased by 26.31% to -$13.2 million in 2022, then rose by 1.65% to -$13.0 million in 2023, then plummeted by 56.98% to -$20.3 million in 2024, then surged by 53.72% to -$9.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$9.4 million, -$15.7 million, and -$17.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.